Actually, because of the cyclical nature of stocks in general, and PTIE in particluar, this little thumbnail from stefaan (translated from Flemish with extraordinary effort by the BLUE HP manager) might be timely.  If anything in it is wrong, we will take our cue from the NASDAQ management, and blame the English-Flemish dictionary.

Products & Trial Phases

PTI 601	tramadol + low dose antagonist	        P2B		tramadol							
PTI 701	hydrocodone 5mg/acetominophen 500 mg	P2						
PTI 555	oral morphine				P2B			
PTI 801	fast release oxycodone + naltrecone     IND		$500m market:bone cancer pain/lower back pain		
PTI 501	intravenous M			p2	1999								
They talk about 5 products, where is the 5th?  For PTI 501 is apparently dead.

Clinical status			

product	date	phase	status	patients	dose	results						
PTI 555	10/23/00 2a	ended	300	      ranging	
25% better pain relief compared to same dose of M alone, same side effects postsurgery
	
PTI 555	10/23/00 2b	open	200			 for post-surgery							
		2b	open	200					
PTI 601	02/22/01	2b	completed	350		results available in 3q 2001; compared to tramadol and placebo for oral surgery											
PTI 701	10/03/00	2	ended	300		
29% better pain relief P 0.046	compared to 5mg hydrocodone/500mg acetominophen and placebo for oral surgery

Expected near term events & questions

when	what				?	
3q 2001	PTI 601 2b results	   why so long	

Why did they stop with PTI 501?	 stefaan seems to think this one had promise.					

Misc.  financial data							
hi 	$26.37		
lo	$5.4		
shares	26.8m	        price   $7.3/sh
mc	$195.64m	cash	$2.8/sh
			
76m$ Cash end 			
loss 0.09$/s/q